Cargando…
Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
Management of advanced hepatocellular carcinoma (HCC) is still a challenge to physicians since these patients are not candidates for surgical or ablative therapy. The disease carries a very poor prognosis with an expected survival of 4–6 months. No chemotherapeutic agent has been proven to improve t...
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Medknow Publications
2008
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2702892/ https://www.ncbi.nlm.nih.gov/pubmed/19568496 http://dx.doi.org/10.4103/1319-3767.37808 |